Conmed (CNMD) Liabilities and Shareholders Equity (2010 - 2026)

Conmed (CNMD) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $2.3 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity fell 1.21% year-over-year to $2.3 billion; the trailing twelve-month figure through Jun 2026 stood at $9.3 billion (changed 0.17% YoY), and the FY2025 full-year result was $2.3 billion, up 0.85% from the prior year.
• Liabilities and Shareholders Equity fell to $2.3 billion in Q2 2026 per CNMD's latest filing, from $2.3 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $2.3 billion in Q2 2025 and bottomed at $1.8 billion in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $2.3 billion across 5 years, with a median of $2.3 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity surged 30.67% in 2022, then dropped 1.6% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $2.3 billion in 2022, then advanced by 0.11% to $2.3 billion in 2023, then advanced by 0.27% to $2.3 billion in 2024, then advanced by 0.85% to $2.3 billion in 2025, then declined by 1.09% to $2.3 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $2.3 billion, $2.3 billion, and $2.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.